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42 Oligomer Binding and Synaptotoxicity
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Abstract
Amyloid beta (Abeta) 1–42 oligomers accumulate in brains of patients with Mild Cognitive Impairment (MCI) and disrupt
synaptic plasticity processes that underlie memory formation. Synaptic binding of Abeta oligomers to several putative
receptor proteins is reported to inhibit long-term potentiation, affect membrane trafficking and induce reversible spine loss
in neurons, leading to impaired cognitive performance and ultimately to anterograde amnesia in the early stages of
Alzheimer’s disease (AD). We have identified a receptor not previously associated with AD that mediates the binding of
Abeta oligomers to neurons, and describe novel therapeutic antagonists of this receptor capable of blocking Abeta toxic
effects on synapses in vitro and cognitive deficits in vivo. Knockdown of sigma-2/PGRMC1 (progesterone receptor
membrane component 1) protein expression in vitro using siRNA results in a highly correlated reduction in binding of
exogenous Abeta oligomers to neurons of more than 90%. Expression of sigma-2/PGRMC1 is upregulated in vitro by
treatment with Abeta oligomers, and is dysregulated in Alzheimer’s disease patients’ brain compared to age-matched,
normal individuals. Specific, high affinity small molecule receptor antagonists and antibodies raised against specific regions
on this receptor can displace synthetic Abeta oligomer binding to synaptic puncta in vitro and displace endogenous human
AD patient oligomers from brain tissue sections in a dose-dependent manner. These receptor antagonists prevent and
reverse the effects of Abeta oligomers on membrane trafficking and synapse loss in vitro and cognitive deficits in AD mouse
models. These findings suggest sigma-2/PGRMC1 receptors mediate saturable oligomer binding to synaptic puncta on
neurons and that brain penetrant, small molecules can displace endogenous and synthetic oligomers and improve
cognitive deficits in AD models. We propose that sigma-2/PGRMC1 is a key mediator of the pathological effects of Abeta
oligomers in AD and is a tractable target for small molecule disease-modifying therapeutics.
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plasticity [9–20] and concomitant failure of memory formation
mechanisms in Alzheimer’s patients [21–26]. Several candidate
receptors for oligomers have been proposed in the literature
[9,11,13,27–29]. In a separate publication we have shown that
screening a small molecule library in a phenotypic assay for
membrane trafficking in mature (21 days in vitro) cultures of

Introduction
Age-dependent accumulation of amyloid beta 1–42 (Abeta)
protein leads to self-association and soluble oligomer formation
[1–8]. Abeta oligomers bind specifically and saturably to neurons,
triggering a variety of changes that result in inhibition of synaptic
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cells per cm2 in 384-well poly-D Lysine coated plates (Greiner) in
Neurobasal Media (Life Technologies) supplemented with B27
(Life Technologies), Glutamax (Life Technologies) and antibiotics
(penicillin, 50 units/ml and streptomycin 50 mg/ml, Life Technologies). Cultures were maintained at 37uC in 5% CO2 with
weekly media change for 3 weeks prior to experimentation. These
mixed cultures of hippocampal plus cortical neurons and glia were
used for all of the in vitro experiments described.

neurons resulted in the discovery of distinct classes of novel
compounds that exhibit key therapeutic properties: these compounds both prevent and reverse the effects of Abeta oligomers on
membrane trafficking, block and displace the binding of Abeta
oligomers to neuronal cultures, restore the loss of synapses caused
by Abeta oligomers, and restore cognition in mouse models of
Alzheimer’s Disease [30]. In this study our approach was to use
these small molecule drug candidates to identify and characterize
the receptors that modulate the binding and neuronal actions of
Abeta oligomers [30].
These oligomer blocking molecules bind selectively with high
affinity to the sigma-2 receptor. The sigma-2 receptor has been a
pharmacological target for treatment of several CNS disorders
including anxiety, depression and stroke [31], and was recently
identified as the protein PGRMC1 [32]. PGRMC1 is a highly
conserved heme-binding protein in the membrane associated
progesterone receptor (MAPR) family that has been shown to
stabilize surface receptor expression of proteins and directly
associates with proteins that regulate membrane trafficking
[33,34]. PGRMC1 is widely expressed in brain at low levels,
where it is enriched in the post-synaptic density fraction [35]. It is
also expressed outside the CNS, and translocates from the
endoplasmic reticulum to the plasma membrane in several cell
types [31,33,34]. More recently, sigma-2/PGRMC1 has been
described as a possible drug target in cancer where it is
overexpressed in tumor cells [36], but it has not been previously
associated with AD.
We validated this receptor’s role in mediating Abeta oligomerinduced signaling by measuring oligomer binding and signaling
following siRNA-induced knock-down of PGRMC1 protein, or in
the presence of selective antibodies directed against various regions
on the PGRMC1 protein. We also examined whether specific
PGRMC1 antibodies and sigma-2 selective small molecules were
able to displace endogenous human Abeta oligomers from unfixed
frozen Alzheimer’s patient brain sections. We have identified the
sigma-2/PGRMC1 protein as a critical receptor mediating greater
than 90% of Abeta oligomer binding to neurons and their
downstream synaptotoxic effects. Small molecules that prevent
and competitively displace Abeta oligomers from neurons in vitro
and Alzheimer’s patient brain tissue are effective at improving
cognitive deficits in animal models of AD following acute and
chronic systemic administration [30].

Oligomer Preparation
Abeta oligomers were prepared at high (100 mM) concentration
according to published methods [37,38]. An Abeta monomer film
was prepared by evaporating 0.253 mg Abeta 1–42 dissolved in
1,1,1,3,3,3,hexafluoro-2-propanol at room temperature for 20 min
using N2 gas. The film was then dissolved in anhydrous DMSO
and diluted to 100 mM with cold Basal Medium Eagle media
(BME, Life Technologies catalog 21010), followed by incubation
at 4uC for 24 hour to form oligomers. The resulting oligomer
preparations were centrifuged at 16,0006g to pellet any insoluble
fibrils and the supernatant was diluted in Neurobasal media prior
to addition to cultures at the final concentrations listed in each
figure legend. Monomeric Abeta peptides were purchased from
California Peptide Inc (catalog number 641-15), American Peptide
Company (catalog number 62-0-80), and the University of
Pittsburgh Peptide Core facility (primary sequence DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA).
All
studies using synthetic oligomers were performed with this
preparation unless otherwise specified.

Trafficking Assay
Neurons were treated with compounds and/or Abeta oligomer
preparations (0.086% DMSO in culture media) and incubated for
1 to 24 hour at 37uC in 5% CO2. Tetrazolium salts (3-(4,5dimethylthiazol-2yl)-2,5diphenyl tetrazolium bromide, Roche
Molecular Biochemicals) were added at a final concentration of
0.75 mM and incubated at 37uC for 60–90 min. Vesicular
formazan remaining in cells was quantified by absorbance
spectrometry (590 nm with 690 nm subtracted) following extraction with 1.6% Tween-20. All compounds were tested in
quadruplicate wells for each concentration in at least 8 replicate
experiments with data from all experiments pooled for analysis
with means 6 S.E.M.

Materials and Methods
Sigma-2 radioligand binding

Animal Welfare

Radioligand competition assays were performed in membranes
from Jurkat cells using 5 nM [3H]1,3-di(2-tolyl) guanidine in the
presence of 1 mM (+)-pentazocine with 10 mM haloperidol to
define non-specific binding [39].

These studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health, 8th Ed.
The protocol was approved by the Institutional Animal Use and
Care Committees at Cognition Therapeutics Inc. and the
University of Kentucky.

Ex vivo autoradiography studies
Quantitative autoradiography studies on frozen unfixed serial
tissue sections from normal (N = 4) or Alzheimer’s disease (N = 4)
postmortem patients’ neocortex were conducted and quantified
according to previously published procedures [40]. [3H](+) pentazocine was used as the radioligand for sigma-1 receptors and
[125I]RHM-1 (American Radiolabelled Chemicals, Inc.) or
[3H]DTG (1,3-Di-(2-tolyl)guanidine (Perkin Elmer) in the presence
of 1 mM (+) pentazocine for sigma-2 receptors [32]. Human brain
samples for these studies were obtained with written consent as
previously published [40].

Neuronal Cultures
All procedures were approved by the Institutional Animal Care
and Use and Committee at Cognition Therapeutics and were in
compliance with the Office of Laboratory Animal Welfare and the
Guide for the Care and Use of Laboratory Animals, Eighth
Edition.
Sprague-Dawley rats, 18 days pregnant, were euthanized by
CO2 asphyxiation followed by cervical dislocation, and embryos
were removed. Hippocampus and cortical tissue from the embryo
brains were digested in 2.5% Trypsin (Life Technologies) to
dissociate cells. Isolated cells were plated at a density of 4.66104
PLOS ONE | www.plosone.org
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1 ng/ml C-terminal antibody to sigma-2/PGRMC1 (Everest
Biotechnology EB07207) or vehicle for 60 min at room temperature and then fixed and labeled with an antibody specific to
Abeta (AW-7, gift from Dominic Walsh [41]) and Cy3-conjugated
secondary antibody. Amyloid plaques were labeled with 0.05%
Thioflavin-S (Sigma) in 50% ethanol for 8 min before treatment
with 80% ethanol for 30 s. Sections from 6 separate donor brains
were used for each treatment group. Fluorescent images of the
sections were analyzed in ImageJ [42] analysis software using a
custom macro which first identifies dense core plaques labeled by
Thio-S and then measures the average Abeta labeling intensity in
a 2 micron wide ring surrounding each plaque. A total of 346 to
464 plaques from six donor specimens were analyzed for each
treatment group. The median intensities of Abeta labeling in the
two micron area surrounding each plaques were calculated for
each section (6 sections per treatment group) and subjected to
multivariate correlation analysis (Spearman’s test) to compare
treatment effects across all donor brain samples.

Abeta binding Assay
To assess the ability of test compounds to prevent the binding of
Abeta oligomers, cultures were treated with compounds for 30
minutes, followed by synthetic Abeta 1–42 oligomer preparation
treatment for 60 min (total Abeta concentration 0.5 mM, equivalent to Kd concentration). Alternatively, displacement of prebound oligomers was evaluated by adding oligomers 60 min prior
to the addition of compounds, followed by additional 30 minutes
incubation. Cells were fixed with 3.75% formaldehyde for 15 min,
blocked with 5% normal goat serum and 0.5% Triton X-100 and
incubated with primary antibodies for Abeta (1 mg/ml 6E10 or
4G8, Covance catalog numbers SIG-39320 and SIG-39330,
respectively), MAP-2 (0.2 mg/ml Chemicon), Synaptophysin-1
(1 mg/ml, Anaspec), glial fibrillary acidic protein (GFAP, 1 mg/
ml, Thermo-Fisher) and fluorescently labeled secondary antibodies
(2 mg/ml, Invitrogen). Images were acquired on a Cellomics VTi
automated microscope with a 20X, 0.75 NA objective and
analyzed using ThermoFisher/Cellomics Neuronal Profiling
bioapplication set to measure punctate labeling of Abeta and
synaptophysin-1 along MAP-2 labeled neurites. For each replicate
experiment, at least 100 neurons were sampled from 4 replicate
wells for each experimental condition (400 to 500 neurons per
experimental condition). The number of replicate experiments is
reported for each experiment. All data presented for Abeta
binding to neurons represents total intensity of Abeta label in
neurite spots per neuron, in relative fluorescent units (RFU), unless
otherwise indicated.
For correlation analyses, total intensity of PGRMC1 in cell
bodies and in neuronal puncta was calculated for each neuron.
Neurons were sorted into bins according to their PGRMC1
expression in each compartment, relative to the expression level in
the population of cells, such that bins for 22 SD, 21 SD, 20.5
SD, +0.5 SD, +1 SD, +2 SD and .+2 SD were created. For each
binned population, the Mean 6 S.E.M. for total PGRMC1
expression in the cell body was graphed vs. the total Abeta labeling
intensity in neurite puncta and correlation statistics were
calculated.

Statistical Analysis
For all experiments involving quantification of Abeta immunofluorescent intensity, at least four replicate, multiwell plates were
analyzed, with a minimum of 4 replicate wells per condition on
each plate and 16 fields imaged per well. Averages of total puncta
intensity per neuron (approx. 90 neurons per well) were calculated
for each well analyzed. These well averages were tested for
normality using a KS distance test before being analyzed for
treatment differences using ANOVA and Bonferroni’s multiple
comparison post-test or pairwise Student’s t-test as indicated.

Results
CogRx compounds are ligands for the sigma-2/PGRMC1
receptor
Cognition Therapeutics (CogRx) molecules CT0093, CT0109,
CT01344 and CT01346 have been demonstrated to reverse Abeta
oligomer-mediated trafficking deficits and restore synapses to
normal and restore cognitive function in mouse models of
Alzheimer’s disease [30]. Active CogRx molecules were counterscreened for activity at 100 central nervous system receptors and
enzymes (including those involved in neurotransmission and
synaptic plasticity) in industry-standard assays measuring radioligand binding displacement and signaling activity (assays performed
at Cerep/Eurofins, Inc., Table S1). Active molecules were 10–100fold selective for the sigma-2/PGRMC1 receptor and competitively
displaced selective radioligands from homogenates of a human B
cell line (Fig. 1A, Ki values (nM): CT0093 = 54611, CT0109
= 967, CT01344 = 4866, CT01346 = 5063, mean 6 S.E.M.).
To determine if these compounds were capable of displacing
binding to sigma-2/PGRMC1 receptors in human brain, CT0093
and CT0109 were added in increasing concentrations to serial
sections of unfixed frozen cognitively normal elderly human frontal
cortex in the presence of a specific radioligand for sigma-2/
PGRMC1, 125I-RHM-4 [31] (Fig. 1 B–D). CT0109 and CT0093
both displaced the specific binding of this radioligand from human
tissue (Ki = 57623 and 33612 nM respectively, Fig. 1B, E). This
evidence demonstrates that these small molecules previously shown
to block Abeta oligomer effects in vitro and in vivo are in fact sigma2 selective ligands.

siRNA
Neuronal cultures were treated with either a mixture of 4
siRNAs targeted against PGRMC1 (GUCUAGGUCUUGGAUAAUA, GGUUUUACCUCAAAUCAGA, UUAGAAUGCAUGAUGUGUU, CUUCUAUCUGUAGUUAAAA, catalog
number A-095365-00-0050) or a non-targeting sequence (UGGUUUACAUGUUUUCCUA, catalog number D-001910-03-50,
Accell, ThermoFisher). siRNA were resuspended to 100 mM in
RNase free water, shaken for 1.5 hours at 37uC, diluted in media
and applied to cells at 1 or 2 uM for 48 hours prior to addition of
Abeta oligomers for 30 minutes. Cultures were then fixed and coimmunolabeled with 6E10 antibody to detect Abeta and antibody
to detect PGRMC1 as described above and analyzed via
automated image processing as described above. For PGRMC1
measurements, total intensity in cell bodies was measured.

Human tissue ex-vivo Abeta competition
Brains from human subjects with a diagnosis of AD (CERAD
score ‘‘definite’’ by postmortem neuropathological exam) were
obtained through the Massachusetts Alzheimer’s Disease Research
Center and Massachusetts General Hospital (MGH) Neuropathology Department, and experiments were approved by the
Massachusetts General Hospital and Harvard Medical School
Institutional Review Board. Serial 10 micron sections of frozen
parahippocampal gyrus on glass slides were incubated with
identical volumes of PBS containing 5 or 15 mM CT01344, or
PLOS ONE | www.plosone.org
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positively correlated with Abeta oligomer binding
Sigma-2/PGRMC1 has been shown to be expressed in postsynaptic densities in rat brain tissue [35]. Previous reports in tumor
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Figure 1. Anti-Abeta compounds are ligands for sigma-2/PGRMC1 receptor. A, CT0109, CT0093, CT01344 and CT01346 displace the
fiduciary sigma-2 ligand [3H]-DTG from receptors on human B cell lines. B. Autoradiograms of 18.4 nM [125I]RHM-1 binding to human frontal cortex
slices in the presence of 10, 100, 1000, 10,000 nM of CT0109 and CT0093, N = 4. Color bar under images show false coloring scale. [125I]RHM-1 displays
specific saturable binding to human frontal cortex tissue as assessed by quantitative autoradiography in dose-response format (C) and as a Scatchard
plot (D). E. Dose response curves for data obtained from autoradiograms in B. The Ki’s for CT0109 and CT0093 at the [125I]RHM-1 binding site were
57623 nM and 33612 nM, respectively.
doi:10.1371/journal.pone.0111899.g001

cells indicate that PGRMC1 protein is localized to intracellular
compartments and the plasma membrane [32–34]. Immunofluorescent labeling of untreated 21 days in vitro (DIV) mixed hippocampal
and cortical cultures with a selective antibody directed against Cterminal amino acids 185–195 showed sigma-2/PGRMC1 is
expressed at low levels in cell bodies of neurons and glia, and in
proximal neurites (Fig. 2A–D, red). In smaller caliber neurites,
sigma-2/PGRMC1 can also be detected in immunoreactive puncta
adjacent to synaptophysin-immunoreactive (Fig. 2A–D, green)
presynaptic terminals, consistent with a post-synaptic localization.
An average of 66.7%62.4 (average 6 S.E.M., N = 110 neurons) of
PGRMC1 positive puncta on neurons colocalize with synaptophysin
positive puncta (Fig. 2A–D, yellow). Sigma-2/PGRMC1 has a
transmembrane region from amino acid 20 to 43 [34], therefore the
C-terminus would be predicted to be intracellular, however the
orientation of the protein when it is present in the plasma membrane
is unclear [34]. Control experiments confirm that a substantial
amount of the protein exists at the plasma membrane with the Cterminal end (amino acid 185–195) exposed to the extracellular
surface (Fig. S1).
Neuronal cultures treated with Abeta oligomers (400 nM) for
1 hour and co-immunolabeled for Abeta, sigma-2/PGRMC1,
MAP2 (to distinguish neurons from glia) and DAPI (to label
nuclei), exhibit a range of sigma-2/PGRMC1 expression levels in
their cell bodies and synaptic puncta (Fig. 2 E–H), as do control
cultures not treated with Abeta oligomers (Fig. 2I–L). We
analyzed expression levels of sigma-2/PGRMC1 and binding
PLOS ONE | www.plosone.org

intensity of Abeta oligomers within each cell to see if they were
positively correlated. We focused on the neuronal population for
this analysis because 1) oligomers bind specifically and saturably to
a single receptor site on neuronal synaptic puncta
(Kd = 518641 nM), whereas the subset of the glial population
that binds Abeta does so at 10-fold lower intensities than the
binding to neuronal synapses and binds monomer and oligomers
equally well, 2) oligomers are 10-fold more potent than monomers
at inducing functional changes in membrane trafficking and
causing synaptotoxicity and memory deficits in vivo [21], 3)
oligomer binding to neuronal synaptic puncta is highly correlated
with downstream functional changes in membrane trafficking rate,
and 4) oligomer binding to synaptic puncta causes synapse
regression that is reversible by washout [20,30]. Examination of
individual Abeta oligomer-treated neurons reveals that neurons
with more intense Abeta oligomer binding to synaptic puncta had
higher expression of sigma-2/PGRMC1 in both their cell body
and synaptic puncta (Fig. 2E–H). Dividing the cell population
into sigma-2/PGRMC1 intensity bins for each compartment
(according to the number of standard deviations from the
population mean) allows this correlation to be seen quantitatively
(Fig. 2M, N). This relationship is statistically significant for both
the cell body expression of sigma-2/PGRMC-1(Kruskal-Wallis
p,0.001) and for expression of sigma-2/PGRMC1 in synaptic
puncta (Kruskal-Wallis p,0.001), suggesting that binding of Abeta
to hippocampal and cortical neurons is positively correlated with
sigma-2/PGRMC1 expression.
4
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Figure 2. Sigma-2/PGRMC1 protein localizes to synaptic puncta on mature primary hippocampal cultures (21 days in vitro) and
expression levels are positively correlated with Abeta oligomer binding. sigma-2/PGRMC1 (A–D, red) is expressed at low levels in
untreated cultures and is localized in cell bodies of neurons and glia, in neurite shafts, and adjacent to presynaptic puncta (A–D, synaptophysin =
green) B. 66.7%62.4 (average 6 S.E.M., N = 110 neurons) of PGRMC1 positive puncta on neurons co-localize (yellow) with synaptophysin positive
puncta. E–L. Positive correlation between sigma-2/PGRMC1 expression and Abeta oligomer binding in neurons (Abeta oligomers = 400 nM, 1 hour
treatment). E–H. Only one neuron (MAP2 positive arrow #1 in E–H) in this field is labeled with punctate Abeta oligomer binding (G), and exhibits
elevated PGRMC1 expression (H, 3.36105 RFU) compared to surrounding neurons (#2 = 1.66105, #3 = 1.86105 RFU). I–L. Vehicle-treated cultures
express a similar range of sigma-2/PGRMC1 expression in neurons (arrow #1 in I = 2.626105, #2 = 1.216105 RFU). All scale bars = 20 microns. M,
Binning neurons according to their intensity of sigma-2/PGRMC1 immunofluorescence and graphing the average values for Abeta binding from each
bin reveals a positive correlation between the intensity of Abeta oligomer binding to synaptic puncta and the expression of sigma-2/PGRMC1 in the
cell body that is significant (Kruskal-Wallis, p,0.001). N. A similar analysis of sigma-2/PGRMC1 imunofluorescence in the synaptic puncta also shows a
positive correlation with Abeta oligomer binding intensity to synaptic puncta (Kruskal-Wallis p,0.001).
doi:10.1371/journal.pone.0111899.g002

1 hour (Fig. 3). This data suggests that Abeta oligomer treatment
causes a progressive upregulation of sigma-2/PGRMC1 expression in neurons.
While Abeta oligomer binding correlates positively with sigma2/PGRMC1 expression following 1 hour of Abeta oligomer
treatment (Fig. 2), it is not possible to analyze whether the

Abeta oligomer treatment causes progressive
upregulation of sigma-2/PGRMC1 expression
The total intensity of sigma-2/PGRMC1 expression in the cell
body of the pooled population of neurons and glia increases by
13% (63.2 S.E.M.) after 24 hours of Abeta oligomer exposure and
28% (63.7 S.E.M.) after 48 hours of exposure, but not after
PLOS ONE | www.plosone.org
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Figure 3. Abeta oligomer treatment causes progressive upregulation of sigma-2/PGRMC1 expression. Expression of sigma-2/PGRMC1
in the cell body of the entire culture cell population significantly increases with time of exposure to Abeta oligomers (A, C, E, 400 nM Abeta
oligomers, *p = 0.05, ***p = 0.001, Student’s t-test, N.1500 neurons and glia per condition) compared to vehicle-treated cultures (B, D, F). All scale
bars = 20 microns. G. Immunofluorescent intensity of sigma-2/PGRMC1 in Abeta oligomer-treated cells, relative to vehicle treatment, at 1 hr, 24 hr
and 48 hr.
doi:10.1371/journal.pone.0111899.g003

increase in PGRMC1 expression by treatment with Abeta
oligomers at 24 or 48 hours is associated with an increase in
Abeta binding. The progressive internalization of bound Abeta
oligomers with treatment times greater than 1 hour complicates
measurements of binding intensity at these longer time intervals
[30].

Sigma-2 receptors are expressed in human brain and are
dysregulated in Alzheimer’s patients
Serial sections of human frontal cortex from age-matched
normal control and AD patient brains were treated with
radioligands specific for sigma-2 receptors ([125I]RHM-4) or for
the unrelated protein sigma-1 ([3H]-(+)-pentazocine) and analyzed
by autoradiography for binding of the radioligands. Similar to
previous reports, sigma-1 receptor exhibited a 54% decline in
expression levels in AD patient brains vs. age-matched cognitively
normal individuals (Fig. 5A, C 4 normal, 4 AD patient brains
[CDR stage 3], p = 0.0375, Student’s t-test), in parallel to the
decline in FDG-PET signal and neuronal loss seen as AD
progresses[43]. Because the AD patient brain samples examined
are CDR stage 3 (severely demented) and therefore likely have a
significant degree of cell loss, this suggests that sigma-1 receptor
expression remains constant in surviving neurons in AD brain
(however we did not measure cell loss directly in these cases). In
contrast, incubation of adjacent tissue sections from these same
brains with radiolabeled sigma-2/PGRMC1 ligand [125I] RHM-4
[32] (Fig. 5B, D) indicates that the level of sigma-2 receptors in
AD patients are not different from controls. This could be due to
upregulation of sigma-2 receptors in surviving neurons or a
downregulation in neurons followed by an upregulation in glia; the
present data do not distinguish between these possibilities. This
evidence demonstrates that sigma-2 receptors are espressed in
human neocortex and may be dysregulated in Alzheimer’s disease.
Human mutations in sigma-2/PGRMC1 sequence have not
been specifically studied for association with neurodegeneration
risk, however there is little tolerated genetic variability in this
protein or its family members in the general human population
(Fig. S3), suggesting that the MAPR proteins (Table S2) are
essential.

Reduction of sigma-2/PGRMC1 protein expression in
neuronal cultures decreases binding of Abeta oligomers
Since genetic knock-outs of sigma-2/PGRMC1 are not
currently available, we examined the role of sigma-2/PGRMC1
protein in mediating Abeta oligomer binding by reducing sigma2/PGRMC1 protein expression via siRNA-mediated gene silencing in mixed neuronal/glial cultures. Four pooled siRNA
sequences to the PGRMC1 protein sequence were added to
cultures at 1 or 2 mM final concentration and allowed to incubate
for 48 hours to reduce PGRMC1 protein levels via transcriptional
suppression. Treated cultures were immunofluorescently labeled
to detect Abeta binding and expression of sigma-2/PGRMC1
(Fig. 4A–F). Treatment with siRNA resulted in a reduction in
immunocytochemically detectable sigma-2/PGRMC1 protein in
the neuronal cell body and synaptic puncta of up to 28% (Fig. 4E)
compared to untreated cultures (Fig. 4D), or cultures that had
been treated with non-targeting siRNA (Fig. 4F). The same cells
showed a reduction in Abeta oligomer binding of up to 91%
(Fig. 4B) compared to untreated cultures (Fig. 4A) or nontargeting siRNA treated cultures (Fig. 4C). The reduction in
sigma-2/PGRMC1 protein expression in neuronal cell bodies and
synaptic puncta was highly correlated with the reduction in Abeta
oligomer binding (Fig. 4G, linear correlation for cell bodies,
r2 = 0.799, p = 0.0011; Fig. 4H, linear correlation for synaptic
puncta r2 = 0.554, p = 0.02). The lack of a 1:1 correspondence
between loss of PGRMC1 and Abeta oligomer binding could be
due to a non-stoichiometric relationship between the two proteins,
and/or a differential effect on the brightest Abeta oligomer
binding neuronal population, or both (Fig. S2). These results
demonstrate that Abeta 1–42 oligomers bind directly to sigma-2/
PGRMC1 receptors or a protein closely associated with it.
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Abeta oligomer binding to neurons is displaced by
sigma-2 selective small molecules and a C-terminal
antibody to sigma-2/PGRMC1
We have shown that our sigma-2 selective small molecules are
capable of preventing and displacing Abeta oligomer binding to
mature primary hippocampal and cortical cultures 21DIV [30].
To confirm the role of the sigma-2/PGRMC1 protein in
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Figure 4. PGRMC1 mediates the binding of Abeta oligomers to neurons in vitro. Co-immunolabeling for Abeta oligomer binding (A–C) and
sigma-2/PGRMC1 expression (D–F) in the same field of view in hippocampal and cortical cultures (21DIV). Untreated neurons (A, D) exhibit Abeta
oligomer binding to synaptic sites on neurites and low levels of sigma-2/PGRMC1 expression. In the presence of siRNA to sigma-2/PGRMC1, both
Abeta oligomer binding and sigma-2/PGRMC1 expression are significantly reduced (B, E). Non-targeting siRNA (C, F) has no effect. G. H. Graphs of
immunocytochemically detectable PGRMC1 protein expression associated with neuron cell bodies (G) and synaptic puncta (H), and Abeta oligomer
binding to synapses for each of nine separate experiments (expressed as a percentage of untreated control culture values mean 6 S.E.M.). siRNAmediated reduction in PGRMC1 protein expression of up to 28% results in a corresponding decrease in Abeta oligomer binding by up to 91% (linear
regression for PGRMC1 expression in neuronal cell bodies, r2 = 0.799, p = 0.0011; for PGRMC1 expression in synaptic puncta, r2 = 0.554, p = 0.02).
doi:10.1371/journal.pone.0111899.g004

that oligomers are competitively displaced from receptors at
synaptic sites. Non-immune IgG (Fig. 6C, G and maroon bars in
I) and an N-terminal antibody to sigma-2/PGRMC1 (data not
shown) cannot reduce oligomer binding under either condition.
We have previously shown that our sigma-2 selective small
molecules are capable of preventing and reversing Abeta oligomerinduced membrane trafficking deficits in mature primary 21DIV
hippocampal and cortical cultures (a memory and synaptic
plasticity-relevant measure), but have no effect on membrane
trafficking when added to cultures in the absence of Abeta
oligomers [30]. We attempted to test whether blocking Abeta

mediating the binding of Abeta 1-42 oligomers, we treated cultures
with Abeta oligomers for 30 minutes, then added a C-terminal
specific PGRMC1 antibody to live cultures for 30 minutes, or viceversa. The cells were then fixed and immunofluorescently labeled
to detect Abeta binding (Fig. 6A–H). This antibody, which is
directed against the C-terminal amino acids 185–195 of sigma-2/
PGRMC1, significantly reduced Abeta oligomer binding to
synaptic terminals on hippocampal and cortical neurites regardless
of whether it was added before (Fig. 6D, green bar in I
[prevention], 58% reduction) or after (Fig. 6H, green hatched
bar in I [treatment], 26% reduction) the oligomers. This suggests
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Figure 5. Sigma2/PGRMC1 receptor is present in human neocortex and is upregulated in AD. A. Control receptor expression (unrelated
receptor sigma-1 labeled with [3H]pentazocine 1 nM) declines in advanced AD patient frontal cortex sections vs. age-matched cognitively normal
individuals (N = 4, *p = 0.0375, Student’s t-test). B, adjacent sections from the same individuals labeled with [125I] sigma-2 antagonist RHM-4 (0.2 nM)
reveal sigma-2 receptor expression is not significantly changed in the disease state vs. normal individuals (N = 4). TB = Total binding. NSB = nonspecific binding in presence of 10 fold excess cold ligand. C, D, Quantified values for binding in images shown in A and B expressed as the percent of
specific binding in controls.
doi:10.1371/journal.pone.0111899.g005

oligomer binding with the C-terminal antibody to PGRMC1
would prevent the downstream functional effects of Abeta
oligomers on trafficking. We added the C-terminal antibody
directed against amino acids 185–195 of sigma-2/PGRMC1, nonimmune IgG or 6E10 antibody (which recognizes amino acids 3–8
on the Abeta sequence) to cultures 1 hour before oligomers, and in
the absence of oligomers, and measured the effect on membrane
trafficking rate 24 hours later. Abeta oligomers induce a significant
deficit in trafficking rate compared to vehicle-treated cultures
(Fig. 6J, red bar vs. blue bar). This oligomer-induced trafficking
deficit is prevented by preincubation of the cultures with 6E10
(Fig 6J, red bar vs. orange striped bar), but not with C-terminal
antibody to sigma-2/PGRMC1, or by nonimmune IgG (Fig. 6J,
red bar vs. green and maroon striped bars respectively). However,
in the absence of Abeta oligomers, the C-terminal antibody to
sigma-2/PGRMC1 induces trafficking deficits all on its own
(Fig. 6J, blue bar vs. green bar), while nonimmune IgG and 6E10
do not (Fig 6J, blue bar vs. maroon and orange bars). This
suggests that the observed induction of trafficking deficits is
unlikely to be due to a nonspecific effect of IgG molecules. When
added to living cells, the C-terminal antibody to sigma-2/
PLOS ONE | www.plosone.org

PGRMC1 does not appear to block Abeta-oligomer-induced
deficits because like oligomers it accelerates exocytosis rate. Small
molecule sigma-2/PGRMC1 ligands do not affect the exocytosis
rate in the absence of Abeta oligomers.
These results highlight the critical role that sigma-2/PGRMC1
plays in the synaptic plasticity-relevant process of membrane
trafficking. Sigma-2/PGRMC1 protein directly associates with
proteins that regulate membrane trafficking [33,34], translocating
from endoplasmic reticulum to the plasma membrane [31,33,34]
and stabilizing surface receptor expression of proteins. The
bivalent binding sites of whole IgG molecule may attach to two
PGRMC1 molecules at the plasma membrane extracellular
surface and trap the molecule at the surface or induce
internalization, or affect the protein’s interaction with other
proteins, altering the overall process of membrane trafficking.
However this does not preclude the possibility that smaller IgG
molecules such as Fab fragments could be therapeutically
efficacious at blocking Abeta oligomer-induced trafficking deficits.
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Figure 6. C-terminal antibodies directed against the C-terminus of PGRMC1 prevent (A–D) and displace (E–H) Abeta oligomer
binding to neurons and glia. Abeta oligomers bind to a subset of neurons and glia in mature hippocampal primary neurons 21DIV (A, E, red bar
in I) compared to vehicle-treated (no Abeta) cultures (B, F, blue bar in I). Graphs in I are average of 3 experiments (avg. intensity of Abeta oligomer
puncta + S.E.M., expressed as a percentage of Abeta oligomer-treated condition, difference in binding intensity vs. Abeta oligomer condition *p,
0.05, Student’s t-test). Abeta oligomer binding to cultured neurons is significantly reduced in the presence of C-terminal antibody to sigma-2/
PGRMC1 regardless of whether it is added before (D, green bar in I [prevention], 58% reduction) or after (H, green hatched bar in I [treatment], 26%
reduction) oligomers. This suggests that oligomers are competitively displaced from receptors at synaptic sites. Non-immune IgG (C, G and maroon
bars in I) and an N-terminal antibody to sigma-2/PGRMC1 (data not shown) cannot reduce oligomer binding under either condition. J Effects of
antibodies on membrane trafficking rate in the presence or absence of Abeta oligomers (expressed as a percentage of vehicle-treated in the absence
of Abeta, difference in trafficking rate vs. Abeta oligomer- or vehicle-treated condition *p,0.05, Student’s t-test). The C-terminal antibody directed
against amino acids 185–195 in sigma-2/PGRMC1 does not rescue oligomer-induced deficits, but induces trafficking deficits on its own in the absence
of Abeta oligomers, pointing to a critical role of this protein in normal membrane trafficking.
doi:10.1371/journal.pone.0111899.g006

sections of unfixed postmortem neocortex were incubated in a
fixed volume of solution containing increased concentrations of
CT01344, antibody or vehicle for 1 hour then fixed and
immunolabeled for Abeta and co-stained with Thio-S to detect
amyloid plaques (Fig. 7A). Abeta intensity in the plaque halo
region was measured via automated image processing and
graphed as a percentage of vehicle values (Fig. 7B). CT01344
dose-dependently reduced Abeta immunofluorescence in the 2
micron wide halo (Spearman’s Rho = 20.492, p = 0.038) and the
antibody also reduced Abeta immunofluorescence in the halo (p,
0.05, Student’s t-test). These results demonstrate that endogenous
human Abeta oligomers can be dose-dependently displaced from
tissue binding sites by sigma-2/PGRMC1-selective small molecules and antibodies directed against the C-terminal region of this
protein.

Endogenous Abeta oligomers are displaced from human
AD patient brain sections by a CogRx compound and
antibody to sigma-2/PGRMC1
Koffie et al. [44], reported that a 2 micron wide halo around
dense-core thioflavin-S positive plaques in human AD patient
brain contain an increased concentration of Abeta oligomers
bound to neurons that can be visualized with immunohistochemical detection methods. This same region is associated with a
decreased number of synapses [44,45]. We tested whether
CT01344 and the C-terminal antibody to sigma-2/PGRMC1
were capable of displacing endogenous Abeta oligomers from this
halo region around amyloid plaques in human AD patient brains
(see Fig S4 for patient characterization and description of analysis
algorithm) under non-equilibrium conditions. Adjacent tissue
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did not. This result suggests that there may be functionally distinct
subtypes of sigma-2/PGRMC1 antagonist.

Discussion
Synaptic dysfunction and loss caused by age-dependent
accumulation of synaptotoxic Amyloid beta (Abeta) 1–42 oligomers has been proposed to underlie cognitive decline in
Alzheimer’s disease (AD) [3–8,49]. We have discovered highly
brain penetrant small molecule receptor antagonists that rescue
oligomer-induced synapse loss and membrane trafficking deficits
in vitro, and cognitive deficits in Alzheimer’s mouse models [30].
Counterscreening against a panel of receptors and ion channels
revealed that these small molecules bind selectively and with high
affinity to sigma-2/PGRMC1 receptors. Sigma-2/PGRMC1
receptors are expressed in neurons and glia at low levels in
primary 21DIV mixed hippocampal and cortical cultures, and
oligomer binding to neuronal puncta is positively correlated with
sigma-2/PGRMC1 receptor expression. Abeta oligomer exposure
progressively upregulates receptor expression in vitro, and perhaps
in Alzheimer’s disease as well. Sigma-2/PGRMC1 receptors are
also expressed in human brain at low levels, and are dysregulated
in Alzheimer’s disease. Knock-down of sigma-2/PGRMC1
protein expression reduces oligomer binding up to 90%. CogRx’s
behaviorally efficacious small molecules appear to act as functional
antagonists at the sigma-2/PGRMC1 receptor. These small
molecules, as well as antibodies specific for the C-terminal region
of sigma-2/PGRMC1 can prevent and competitively displace
Abeta oligomer binding to neurons in vitro, and to human
Alzheimer’s patient brain sections in a dose-dependent manner.
Collectively, these data demonstrate that Abeta oligomers bind
directly to sigma-2/PGRMC1 receptors, or a protein closely
associated with it that itself mediates oligomer binding. Regardless
of the precise mechanism, sigma-2/PGRMC1 selective small
molecule antagonists have the potential to be disease-modifying
therapeutics for Alzheimer’s disease patients.
Sigma-2/PGRMC1 translocates between subcellular and plasma membrane locations [33,34,50], and our studies suggest that
the C-terminus of at least part of the plasma membrane-localized
sigma-2/PGRMC1 protein appears to be exposed to the
extracellular environment where it interacts directly with Abeta
oligomers or a protein that directly binds them. While it has been
suggested that the C-terminus of sigma-2/PGRMC1 is on the
cytoplasmic side of cell surface membranes [50], there is evidence
that this domain of the protein can be extracellular [51].
In vitro, the more sigma-2/PGRMC1 is expressed in cells, the
more Abeta is bound to cells and treatment with Abeta oligomers
results in a progressive upregulation of the amount of sigma-2/
PGRMC1 expressed in cells. In the mammalian brain, sigma-2/
PGRMC1 is normally expressed at low levels. In severely
demented Alzheimer’s disease patients (CDR stage 3) expected
to have a high degree of cell loss, the density of sigma-2 receptors
remains unchanged compared to age-matched normal individuals,
while the density of the unrelated sigma-1 receptor is decreased by
54%, as has been previously reported [43]. Collectively, these data
suggests that oligomers may upregulate expression levels of the
receptors that mediate their own binding, contributing to disease
pathology. The consequences of any potential receptor upregulation for eventual drug dosing in human clinical trials are not
expected to be significant, as the total amount of drug present is
typically in vast excess to the number of receptors expressed on
tissue. Studies in cell lines have shown that binding affinity of
drugs to sigma-2/PGRMC1 receptor is constant despite a 10-fold
difference in expression levels (Bmax) of the receptors [52]. To

Figure 7. Antibodies and compounds directed against sigma-2/
PGRMC1 dose-dependently displace endogenous human
Abeta oligomers from specific tissue locations in Alzheimer’s
brain neocortical tissue sections. A, Abeta oligomers located in a 2
micron halo surrounding compact thioflavin-S positive plaques is
displaced from frozen postmortem human AD brain tissue sections
(N = 7 patients) by C-terminal sigma-2/PGRMC1 antibody and receptor
antagonist CT01344 (B) in a dose-dependent manner compared to
vehicle-treated brain sections from the same individual (Spearman’s
rank order, rho = 20.492, p = 0.038). All scale bars = 20 microns. See
Fig. S4 for details on quantification method.
doi:10.1371/journal.pone.0111899.g007

Behaviorally efficacious sigma-2/PGRMC1 selective small
molecules are functional antagonists at the receptor
Little is known about the functional pharmacology of ligands for
the sigma-2/PGRMC1 receptor. In tumor cells, agonists for
sigma-2/PGRMC1 cause toxicity by triggering caspase 3 activation [46,47] whereas sigma-2/PGRMC1 antagonists do not
[47,48]. We tested the behaviorally efficacious compounds
CT0109 and CT0093 [30] to determine whether they behave as
functional agonists or antagonists. In both primary hippocampal/
cortical cultures and in the SKOV-3 tumor cell line, sigma-2/
PGRMC1 agonist siramesine activated caspase-3/7 (Fig. 8A, B)
while CT0109, CT0093 and the sigma-2 antagonist RHM-1 did
not. Similarly, sigma-2/PGRMC1 agonists siramesine, WC-26
and SV-119 caused dose-dependent cell death in mature primary
neuronal cultures (Fig. 8C) and in SKOV-3 human ovarian
cancer cells (Fig. 8D), measured using fluorescent substrates for
caspase-3/7 to detect enzymatic activity, but sigma-2/PGRMC1
antagonists RHM-1, CT0109 and CT0093 did not affect cell
viability except at very high concentrations (.100 mM). These
results indicate that the compounds CT0093 and CT0109 behave
as antagonists in these functional assays. Finally, we treated
hippocampal and cortical cultures with ascending concentrations
of SV119 to induce caspase activation, in the presence of 40 mM of
each of the sigma-2/PGRMC1 antagonists CT0109, CT0093 and
RHM-1 (Fig. 8E). CT0109 and CT0093 significantly blocked the
activation of caspase-3/7 by SV119, but the antagonist RHM-1
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Figure 8. CogRx sigma-2/PGRMC1-selective small molecules are functional antagonists. A, B Sigma-2/PGRMC1 agonist siramesine causes
dose-dependent activation of caspase 3 in primary neuronal cultures (A) and in SKOV-3 human ovarian cancer cells (B) but sigma-2/PGRMC1
antagonists RHM-1, CT0109 and CT0093 do not. C, D Sigma-2/PGRMC1 agonists siramesine, WC-26 and SV-119 cause dose-dependent cell death in
primary hippocampal/cortical cultures (C) and in SKOV-3 human ovarian cancer cells (D) but sigma-2/PGRMC1 antagonists RHM-1, CT0109 and
CT0093 do not, except at very high concentrations (.100 mM). (E) Treatment of cultures of hippocampal and cortical cells with 20 to 80 mM SV-119
for 24 hours induced the activation of caspase 3/7 (*p,0.05 by 2-tailed Student’s t-test compared to control). Co-treatment of cultures with 40 mM
CT0109 or CT0093 did not increase caspase activity and blocked the activation by the agonist SV-119.
doi:10.1371/journal.pone.0111899.g008

competitively displaced from binding sites in dissociated cell
culture and in tissue by small molecule therapeutic agents and
antibodies specific for the same receptor. Using these compounds
to calculate off-rate of endogenous human oligomers, as well as to
investigate the equilibrium between the various structural forms of
Abeta protein found in human and transgenic animal model brain
tissue is the subject of future studies. Much has been made recently
of variability in oligomer preparations [53], however, the fact that
therapeutic compounds and antibodies displace both synthetic and
endogenous human oligomers validates an approach in which
multiple preparations are used and compared in the course of drug
discovery and elucidation of the fundamental underpinnings of
oligomer biology.

date, there are no reports of mutations in sigma-2/PGRMC1 that
are associated with neurodegenerative diseases, human but
mutations in this receptor are very rare, suggesting this gene is
essential. Antibodies specific for the C-terminus of this receptor
disrupt the normal process of membrane trafficking within
neurons and glia in vitro, reinforcing the concept that this protein
is essential for normal function. It is therefore possible that this
protein is critically involved in AD, but understanding its role will
require clinical examination in a large cohort of patients.
There are several reports in the literature of Abeta oligomer
receptors, but this is the first report we are aware of in which
greater than 90% of Abeta oligomer binding could be abolished by
genetic knock-down of the putative receptor. This is also the first
report we are aware of demonstrating that oligomers can be
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allosterically modulating sigma-2/PGRMC1, which in turn alters
the conformation of a tightly associated oligomer receptor protein.
Reduction of sigma-2/PGRMC1 protein expression by siRNA
reduces oligomer binding by eliminating the ability of sigma-2/
PGRMC1 to stabilize the binding conformation of the receptor
protein. The data obtained to date are consistent with either
model. Our compounds’ mechanism of action is also consistent
with both possibilities.
The saturable binding of oligomers to a single site on neurons,
together with the total loss of oligomer binding in the presence of
compound or antibody specific for sigma-2/PGRMC1, would
seem to argue for the first model, however oligomer binding to
another protein that is very tightly linked to sigma-2/PGRMC1
would show the same pattern. It could be argued that support for
the second model comes from the fact that sigma-2/PGRMC1
receptors are ubiquitously distributed both within and outside the
nervous system, yet oligomers only bind to a subset of neurons.
The subcellular localization of sigma-2/PGRMC1 in different
tissues and cell types, and how this localization may change in
response to signaling or damage, is not currently clear. Additional
support for the second model comes from published reports that
PGRMC1 stabilizes plasma membrane localization of EGFR and
mPRa [57,58].
Some support for a model with PGRMC1 modulating a binding
site for Abeta oligomers could come from the lack of a 1:1
stoichiometric relationship between loss of oligomer binding and
loss of PGRMC1 protein expression as detected by immunohistochemistry (Fig. 4). Reduction of sigma-2/PGRMC1 expression
levels of up to 30% in neurons leads to reduction of oligomer
binding up to 91%. The two are highly correlated (r2 = 0.799 for
cell bodies and r2 = 0.554 for synaptic puncta) with a slope of
2.560.5 for correlations with cell bodies and 2.660.5 for
correlation with synaptic puncta, suggesting that for every one
PGRMC1 receptor lost, 2–3 oligomers are not binding. This data
suggests that the relationship between sigma-2/PGRMC1 expression and Abeta oligomer binding may not be strictly stoichiometric
(one sigma-2/PGRMC1 molecule may bind to three oligomers, or
one PGRMC1 may coordinately regulate expression and/or
modulate three molecules which themselves bind Abeta oligomers
directly). The details of this stoichiometry would need to be
examined with quantitative labeling techniques for both sigma-2/
PGRMC1 and Abeta oligomers, which is currently quite
challenging to perform on oligomers without knowing whether
such modifications alter secondary and tertiary structure.
Whether this would be the case for human oligomers in tissue
sections remains to be seen, and would require identification of
equilibrium binding conditions and an understanding of the
stoichiometry between detection antibodies and human oligomers.
The lack of stoichiometry could also be due to a differential effect
of PGRMC1 protein loss on Abeta oligomer binding to a subset of
the neuronal population; the two possibilities are not mutually
exclusive.
The second model is also supported by reports of oligomer
receptor candidates that have appeared in the literature [9–
11,13,27–29]. For several of these candidate receptors, oligomer
binding to neurons (visualized via immunohistochemistry) is
reduced by at most 50% when the receptor levels are eliminated
by genetic knock-out [27,29]. In contrast, siRNA-mediated
reduction of sigma-2/PGRMC1 results in greater than 90%
reduction of oligomer binding with a strong correlation between
the amount of knock down of sigma-2/PGRMC1 protein and the
amount of reduction of oligomer binding (r2 = 0.7994 for cell
bodies and r2 = 0.554 for synaptic puncta). Small molecules
selective for sigma-2/PGRMC1 completely eliminate detectable

The compounds we identified as being capable of displacing the
oligomers appear to act as functional antagonists at the sigma-2/
PGRMC1 receptor because they can block small molecule
agonist-induced caspase activation. If oligomers acted as agonists
in this functional context (i.e., if they induced caspase activation),
the story would be a simple one; oligomers trigger caspasemediated signaling through sigma-2/PGRMC1 and antagonists
block it. However, despite several literature reports that oligomers
induce caspase activation [46,54,55] we have been unable to
detect oligomer-induced caspase activation in 21 DIV primary
hippocampal and cortical neuronal cultures following treatment
for 3–48 hours at Abeta oligomer concentrations up to 28 uM.
Therefore, rigorous designation of compounds as functional
‘‘agonists’’ and ‘‘antagonists’’ in the context of oligomer biology
will await identification of relevant signaling pathways downstream of oligomer interactions with sigma-2/PGRMC1. Candidates proteins include Insig/SCAP, P4, MAP1LC3 and UVRAG,
as well as those mediating cholesterol metabolism [33,34].
Understanding the interaction of sigma-2/PGRMC1 with proteins
involved in intracellular trafficking [56] may further explain the
mechanisms by which Abeta oligomers exert an effect on
membrane trafficking, synaptic plasticity and cognitive loss. It is
interesting to note that even at the level of the well-described
caspase activation downstream of sigma-2 selective ligand binding,
not all functional antagonists appear to be equally effective.
Relevant drug binding sites on sigma-2/PGRMC1 are still coming
into focus. In the meantime, it is clear that the compounds
described in this manuscript are capable of blocking the
synaptotoxic effects of Abeta oligomers that occur via interactions
with sigma-2/PGRMC1, and that they represent potential diseasemodifying therapeutics.

Pharmacological model for compound-receptor
interactions
The accompanying paper [30] presented evidence supporting
the hypothesis that our compounds block the synaptotoxic effects
of Abeta oligomers via allosteric antagonism rather than direct
competitive antagonism. The present results provide additional
evidence favoring the former scenario. Direct competitive
antagonism would not be expected to result in an enhanced
decrease in prebound oligomers from tissue under non-equilibrium binding conditions. Instead the observed dose-dependent
displacement of endogenous oligomers from human Alzheimer’s
brain tissue (Fig. 7) make it more likely that our compound
changes the affinity of the receptor for Abeta oligomers and
increases the off-rate of the oligomers. This experimental result
also makes it unlikely that our compounds reduce oligomer
binding by inducing internalization of oligomer receptors, since
this machinery is not likely to be functioning in frozen tissue
sections.

Pharmacological model for oligomer-receptor
interactions
The data presented here indicate that sigma-2/PGRMC1 is
critically required for binding of Abeta oligomers to neurons,
either as 1) a direct binding site, or 2) by modulating conformation
of a direct binding site. In the first model, small molecule ligands
for sigma-2/PGRMC1 could block the binding of Abeta oligomers
by allosterically modulating sigma-2/PGRMC1 itself, and reduction of sigma-2/PGRMC1 protein expression by siRNA profoundly reduces oligomer binding by directly eliminating the
binding site for Abeta. In the second model, small molecule ligands
for sigma-2/PGRMC1 block the binding of Abeta oligomers by
PLOS ONE | www.plosone.org
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oligomer binding from neurons in vitro and dose-dependently
displace oligomers from Alzheimer’s patient brain tissue. If
oligomers do bind directly to another protein, sigma-2/PGRMC1
likely plays a central role in its regulation. This is supported by
PGRMC1’s demonstrated role in stabilizing surface expression of
transmembrane receptors [57,58]. Additional studies will be
required to test whether there is a direct interaction of sigma-2/
PGRMC1 with candidate oligomer receptors. Given what is
known about the mechanisms of synaptic plasticity, it is possible
that the single, saturable oligomer binding site is in fact part of a
multi-protein receptor complex that may include several of these
candidate receptors. Such a multi-protein complex might change
its constituent proteins depending on the electrical signaling
pattern and history at a given synapse and thus exhibit a statedependency. In contrast to other candidate oligomer receptors,
small molecules with high affinity for sigma-2 receptors have
reached Phase II clinical trials with no apparent mechanism of
action-based toxicity reports. Decades of study have implicated
sigma-2 receptors in several CNS disorders, but it has not been
previously implicated in Alzheimer’s disease or other neurodegenerative disorders. To date, no clinical trials with selective small
molecules targeting this receptor for treatment of Alzheimer’s
disease have been conducted. The identification of the sigma-2
ligand binding activity as the protein PGRMC1 has opened up
new avenues of research into CNS damage and dysregulation, and
the mechanisms that mediate it [32].
Abeta oligomers are formed via self-association of monomeric
protein that builds up with age, and are likely to be structurally
polydisperse in the brain. Oligomer levels correlate with cognitive
function in Alzheimer’s disease [6,59,60]. Our evidence indicates
that oligomers bind saturably to a single binding site on neurons
and can be displaced by small molecule allosteric antagonists. We
have also shown that oligomers bind directly to sigma-2/
PGRMC1 or a protein whose binding site for oligomers can be
modulated by sigma-2/PGRMC1. The high affinity, selective
sigma-2/PGRMC1 compounds that we have discovered are
capable of preventing binding of oligomers and of displacing
bound oligomers, thereby preventing and treating oligomerinduced trafficking deficits and synapse regression. These molecules rapidly prevent and treat cognitive deficits in wild-type and
aged transgenic Alzheimer’s mouse models and sustain this
cognitive improvement long term [30].
Oligomers thus represent pathological ligands that behave
according to the principles of mass action. Brain-penetrant
antagonists to sigma-2/PGRMC1 receptors represent a novel
approach to blocking Abeta oligomer binding and downstream
signaling and are potentially capable of halting disease progression. This is good news for Alzheimer’s patients, for whom no
disease-modifying therapies currently exist.

(S.D.) less intense than that which is detected following
permeabilization with detergent (C), indicating that this region
of the protein is not located exclusively intracellularly. This
suggests that substantial amounts of the C-terminus are likely
exposed on the plasma membrane extracellular surface. Scale bar
= 20 microns.
(TIF)
Figure S2 siRNA-mediated reduction of PGRMC1 ex-

pression reduces the number of neurons that exhibit the
most intense binding of Abeta oligomers. (Note different
y-axis scales) A–D siRNA-treated cultures (black bars) exhibit
fewer cells labeled most brightly with Abeta oligomers compared
to untreated cultures; these neurons also have the highest sigma-2/
PGRMC1 expression. Dividing the cell population into Abeta
oligomer binding intensity bins allows this absence to be seen
quantitatively. siRNA-treated neurons (filled bars) have similar
numbers of neurons as untreated cultures (open bars, A), and
similar numbers of neurons with little (B) or moderate (C)
detectable Abeta oligomer binding to neuritic puncta, but exhibit a
dramatic absence of the most brightly oligomer-labeled neurons
expressing the highest levels of sigma-2/PGRMC1 protein (D)
compared to untreated cultures. In untreated cultures (open bars),
neurons with Abeta oligomer punctate labeling of .300 average
intensity (D) represent 27% of the total neuronal population (A).
Following siRNA treatment (black bars), this neuronal population
decreases to 3% of total. Thus the impact on this bright binding
population may have a disproportionate effect on the population
total binding average. This is one possible reason why siRNAmediated reduction of PGRMC1 protein expression by 30% but
reduces Abeta oligomer binding by 90%.
(TIF)
Figure S3

Figure S4 Method of analyzing endogenous Abeta
oligomer binding displacement from fresh frozen postmortem neocortical Alzheimer’s patient brain sections.
A. Brain tissue section showing ThioS labeling of dense core
plaques and (B) same section immunolabeled for Abeta 1–42. C,
D Enlargement of yellow boxes in A and B showing individual
plaques (C) and corresponding Abeta labeling (D). E, F
Enlargement showing single plaques and Abeta label. G. Outline
of mask drawn around one plaque and 2 mm plaque halo around
edge of plaque by analysis macro. H Mask is transferred to Abeta
immuno-fluorescent channel and intensity in the plaque halos are
measured. I. Table shows characteristics of patients with a
diagnosis of AD (CERAD score ‘‘definite’’ by postmortem
neuropathological exam) used in this study and number of plaques
analyzed in each treatment group from each case. Statistical
analysis of data from this experiment is described in Methods.
(TIF)

Supporting Information
Figure S1 PGRMC1’s C-terminal amino acids 185–195
are exposed at the extracellular surface of the plasma
membrane. Untreated cultures were formaldehyde-fixed then
immunolabeled with anti-synaptophysin antibody. This antibody
can only detect the synaptophysin protein following detergent
permeabilization of the plasma membrane (A), which allows the
large IgG molecule physical access to the intracellularly located
synaptophysin protein. In the absence of detergent, punctate
synaptophysin immunolabeling is not visible (B). In contrast,
cultures immunolabeled with anti-PGRMC1 antibody directed
against the protein’s C-terminal amino acids 185–195 can detect
PGRMC1 in the absence of detergent (D), although it is 55%67
PLOS ONE | www.plosone.org
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species.
(DOCX)

Table S1 Activity of CT0109 in target screening panel.

(DOCX)
Table S2 Genetic analysis of MAPR family members
PGRMC1, PGRMC2, neudesin (NENF) and neuferricin.
(DOCX)
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